

US Dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited

Income statement

	9 months 2024 £m	9 months 2024 \$m
TURNOVER	23,259	29,779
Cost of sales	(6,489)	(8,308)
Gross profit	16,770	21,471
Selling, general and administration	(8,352)	(10,693)
Research and development	(4,370)	(5,595)
Royalty income	463	593
Other operating income/(expense)	(1,186)	(1,519)
OPERATING PROFIT	3,325	4,257
Finance income	88	113
Finance expense	(496)	(635)
Share of after tax profit/(loss) of associates and joint ventures	(3)	(4)
PROFIT BEFORE TAXATION	2,914	3,731
Taxation	(464)	(594)
PROFIT AFTER TAXATION FOR THE PERIOD	2,450	3,137
Profit attributable to non-controlling interests	289	370
Profit attributable to shareholders	2,161	2,767
	2,450	3,137
EARNINGS PER SHARE	53.0p	67.9c
Diluted earnings per share	52.2p	66.9c

In the income statement above US dollar results for nine months period ended 30 September 2024 are calculated using average rates for nine months ended 30 September 2024.

In the detailed sales tables below US dollar results for the nine months ended 30 September 2024 are calculated using average rates for nine months ended 30 September 2024

Vaccines turnover – nine months ended 30 September 2024

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	\$m	\$m	\$m	\$m
Shingles	2,516	1,078	667	771	3,221	1,380	854	987
<i>Shingrix</i>	2,516	1,078	667	771	3,221	1,380	854	987
Meningitis	1,142	580	339	223	1,463	743	434	286
<i>Bexsero</i>	783	325	331	127	1,003	417	424	162
<i>Menveo</i>	337	255	5	77	432	326	6	100
Other	22	–	3	19	28	–	4	24
RSV	432	387	6	39	553	495	8	50
<i>Arexvy</i>	432	387	6	39	553	495	8	50
Influenza	303	244	14	45	388	312	18	58
<i>Fluarix, FluLaval</i>	303	244	14	45	388	312	18	58
Established Vaccines	2,533	1,012	542	979	3,243	1,295	694	1,254
<i>Infanrix, Pediarix</i>	390	206	87	97	499	264	111	124
<i>Boostrix</i>	532	337	104	91	681	431	133	117
<i>Hepatitis</i>	521	295	143	83	667	378	183	106
<i>Rotarix</i>	431	137	88	206	552	175	113	264
<i>Synflorix</i>	157	–	7	150	201	–	9	192
<i>Priorix, Priorix Tetra, Varilrix</i>	240	26	93	121	307	33	119	155
<i>Cervarix</i>	66	–	11	55	85	–	14	71
Other	196	11	9	176	251	14	12	225
Vaccines excluding COVID-19 solutions	6,926	3,301	1,568	2,057	8,868	4,225	2,008	2,635
Pandemic vaccines	–	–	–	–	–	–	–	–
Pandemic adjuvant	–	–	–	–	–	–	–	–
Vaccines	6,926	3,301	1,568	2,057	8,868	4,225	2,008	2,635

Specialty Medicines turnover – nine months ended 30 September 2024

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	\$m	\$m	\$m	\$m
HIV	5,120	3,394	1,109	617	6,555	4,345	1,420	790
Dolutegravir products	4,083	2,520	981	582	5,227	3,226	1,256	745
<i>Tivicay</i>	1,007	566	190	251	1,289	725	243	321
<i>Triumeq</i>	979	682	172	125	1,253	873	220	160
<i>Juluca</i>	496	391	95	10	635	500	122	13
<i>Dovato</i>	1,601	881	524	196	2,050	1,128	671	251
<i>Rukobia</i>	110	104	6	–	141	133	8	–
<i>Cabenuva</i>	703	575	110	18	900	736	141	23
<i>Apretude</i>	195	189	–	6	250	242	–	8
Other	29	6	12	11	37	8	15	14
Respiratory/Immunology and Other	2,389	1,570	409	410	3,059	2,010	524	525
<i>Nucala</i>	1,300	702	335	263	1,665	899	429	337
<i>Benlysta</i>	1,067	866	85	116	1,366	1,108	109	149
Other	22	2	(11)	31	28	3	(14)	39
Oncology	1,002	701	249	52	1,283	898	319	66
<i>Zejula</i>	450	232	174	44	576	297	223	56
<i>Blenrep</i>	1	(3)	4	–	1	(4)	5	–
<i>Jemperli</i>	318	259	52	7	408	332	67	9
<i>Ojjaara/Omjjara</i>	235	213	21	1	301	273	27	1
Other	(2)	–	(2)	–	(3)	–	(3)	–
Specialty Medicines excluding COVID 19 solutions	8,511	5,665	1,767	1,079	10,897	7,253	2,263	1,381
Pandemic	1	–	–	1	1	–	–	1
<i>Xevudy</i>	1	–	–	1	1	–	–	1
Specialty Medicines	8,512	5,665	1,767	1,080	10,898	7,253	2,263	1,382

General Medicines turnover – nine months ended 30 September 2024

	Total £m	US £m	Europe £m	International £m	Total \$m	US \$m	Europe \$m	International \$m
Respiratory	5,407	2,912	1,055	1,440	6,923	3,728	1,351	1,844
<i>Anoro Ellipta</i>	425	192	164	69	544	246	210	88
<i>Flixotide/Flovent</i>	384	259	51	74	492	332	65	95
<i>Relvar/Breo Ellipta</i>	792	300	275	217	1,014	384	352	278
<i>Seretide/Advair</i>	798	273	166	359	1,022	350	213	459
<i>Trelegy Ellipta</i>	2,033	1,512	230	291	2,603	1,935	295	373
<i>Ventolin</i>	532	276	76	180	681	353	97	231
Other Respiratory	443	100	93	250	567	128	119	320
Other General Medicines	2,414	179	521	1,714	3,090	229	667	2,194
<i>Augmentin</i>	474	–	138	336	607	–	177	430
<i>Lamictal</i>	304	123	81	100	389	157	104	128
Other "Other General Medicines"	1,636	56	302	1,278	2,094	72	386	1,636
General Medicines	7,821	3,091	1,576	3,154	10,013	3,957	2,018	4,038

Commercial Operations turnover - nine months ended 30 September 2024

	Total £m	US £m	Europe £m	International £m	Total \$m	US \$m	Europe \$m	International \$m
Commercial operations turnover	23,259	12,057	4,911	6,291	29,779	15,435	6,289	8,055
<i>Commercial operations turnover excluding COVID 19 solutions</i>	<i>23,258</i>	<i>12,057</i>	<i>4,911</i>	<i>6,290</i>	<i>29,778</i>	<i>15,435</i>	<i>6,289</i>	<i>8,054</i>

Balance sheet

	30 September 2024 £m	30 September 2024 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,885	11,910
Right of use assets	840	1,126
Goodwill	6,680	8,955
Other intangible assets	15,010	20,121
Investments in associates and joint ventures	81	109
Other investments	1,023	1,371
Deferred tax assets	6,288	8,429
Derivative Instruments	4	5
Other non-current assets	1,940	2,601
Total non-current assets	40,751	54,627
Current assets		
Inventories	5,918	7,933
Current tax recoverable	484	649
Trade and other receivables	7,383	9,897
Derivative financial instruments	241	323
Liquid investments	20	27
Cash and cash equivalents	3,192	4,279
Assets held for sale	60	80
Total current assets	17,298	23,188
TOTAL ASSETS	58,049	77,815
LIABILITIES		
Current liabilities		
Short-term borrowings	(2,815)	(3,774)
Contingent consideration liabilities	(1,105)	(1,481)
Trade and other payables	(14,375)	(19,270)
Derivative financial instruments	(146)	(196)
Current tax payable	(568)	(761)
Short-term provisions	(2,450)	(3,284)
Total current liabilities	(21,459)	(28,766)
Non-current liabilities		
Long-term borrowings	(13,244)	(17,753)
Corporation tax payable	(19)	(25)
Deferred tax liabilities	(294)	(394)
Pensions and other post-employment benefits	(2,028)	(2,719)
Other provisions	(492)	(660)
Contingent consideration liabilities	(6,020)	(8,070)
Other non-current liabilities	(1,040)	(1,394)
Total non-current liabilities	(23,137)	(31,015)
TOTAL LIABILITIES	(44,596)	(59,781)
NET ASSETS	13,453	18,034
EQUITY		
Share capital	1,348	1,807
Share premium account	3,473	4,656
Retained earnings	8,187	10,974
Other reserves	1,000	1,341
Shareholders' equity	14,008	18,778
Non-controlling interests	(555)	(744)
TOTAL EQUITY	13,453	18,034

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 September 2024